Board of Directors
Company Risk
- The increase in the number of service providers, including hospitals, specialized clinics, and new market entrants, may intensify competition in attracting patients. This could result in a decline in the Company’s patient volume or market share and may adversely affect overall business revenue. - Heightened competition may also lead service providers to reduce prices or offer promotional campaigns to attract customers, which could negatively impact profit margins. - The Company may need to increase its budget for marketing, public relations, branding, and customer access channels in order to retain existing customers and attract new ones. - Competition in the IVF industry is often driven by advanced medical technologies, treatment success rates, and the expertise of medical professionals. Therefore, the Company may need to invest further in medical technologies and laboratory facilities, which could lead to higher operating costs.
When compared to other infertility treatment centers in the market, the Group has many competitive advantages. Both in terms of the long-established reputation, location, as well as the quality and modern service standards of the Group. The Company acknowledges the risk of competition and has therefore established a quality policy for efficient organizational development. The risk management policy aims to establish a sustainable competitive advantage, including access to services in branches located in key tourist destinations within the country. This is done to cater to consumer needs and ensure their access to the services provided by the Group. The quality policy encompasses advancements in medical practices, compliance with relevant laws, regulations, and requirements, and emphasizes the provision of comprehensive services through innovative approaches. The development of staff capabilities to meet consumer demands is also prioritized. Based on this organizational development policy, the Company believes it can effectively create a sustainable competitive advantage.
- If suppliers are unable to deliver products as scheduled, or if shortages occur in medications, medical supplies, or laboratory reagents, certain medical services or diagnostic procedures may be delayed or unable to proceed as planned. - Price volatility or increases imposed by suppliers may result in higher costs for medications, medical supplies, equipment, and reagents, which could adversely affect the Company’s profit margins.
To effectively manage the risk of relying on manufacturers or distributors in the future, the Company has implemented a procurement policy for pharmaceutical products and medical supplies. The policy includes sourcing from domestic manufacturers or distributors representing foreign manufacturers who meet the Company's standards. Additionally, an Approved Vendor List has been created, considering various factors such as licensing and certification requirements, including ISO, CE, or TIS certifications, as well as compliance with regulations set by the Food and Drug Administration (FDA). Thailand has the capability to procure high-quality pharmaceutical products and medical supplies that are renowned and meet the requirements of healthcare professionals. The Company's selection criteria also consider the supplier's financial stability and adherence to standardized delivery systems. Notably, the Company has not had any exclusive or unique contractual obligation regarding the procurement of medicines, medical supplies, medical materials, or medical devices with any specific supplier. The Comapny is confident in its ability to effectively manage the risks associated with purchasing pharmaceutical products, medical supplies, and analytical reagents for laboratory analysis. This is due to the Group's history of establishing and maintaining strong relationships with manufacturers of pharmaceuticals, medical supplies, and laboratory analytical reagents. The Group ensures timely and complete payments, consistently adhering to its procurement policies. The Group has a dedicated department responsible for systematically and continuously overseeing risk management in this area. Regular discussions and meetings are conducted to monitor inventory levels and proactively plan future orders for pharmaceuticals, medical supplies, and medical devices. Additionally, the Group maintains positive relationships with other distributors, allowing it to source drugs and medical supplies from alternative suppliers beyond those previously mentioned. Consequently, the Group has never encountered any issues or shortages in ordering pharmaceutical products, medical supplies, and analytical reagents for laboratory analysis in the past.
The outbreak of COVID-19 in the past had a significant impact on the Company’s international customers, who represent a key customer segment. As a result, the Company’s operating performance was materially affected.
During the epidemic, the Company's executives and relevant departments closely monitored news that may impact the Company, allowing them to develop appropriate response plans if a communicable disease were to occur. This includes building a positive image that instils confidence in using the services provided by the Company's infertility treatment centers. Specific measures are implemented to ensure the safety of customers, such as requiring the use of masks throughout working hours and scheduling appointments appropriately for each patient. Additionally, medical equipment and operating rooms are properly conducted to comply with established standards. Additionally, amidst the COVID-19 epidemic and travel restrictions that significantly affected the influx of foreign customers seeking services from the Group, the Company has adjusted its business strategy to align with the prevailing circumstances. By targeting the local Thai customer base during this period, the Company could mitigate the impact to a considerable extent and generate a net profit from its operations amidst the COVID-19 outbreak. Currently, the COVID-19 epidemic situation in Thailand is gradually improving, leading to increased relaxation of entry measures as the country reopens to international tourists. Consequently, foreign customers have begun to return and use the services. However, the Company remains vigilant, closely monitoring news that may impact its operations in order to effectively manage business activities according to the established operational plan.
The Company is exposed to the risk of non-compliance with laws and regulations related to Assisted Reproductive Technology (ART), which may result in license revocation, legal actions, loss of revenue, diminished patient confidence, and a material impact on the continuity of the Company’s operations.
The Group recognizes the significance of adhering to announcements, regulations, and relevant laws, and prioritizes compliance with applicable announcements, rules, regulations, and laws. It has a policy in place to ensure that responsible personnel actively and consistently monitor, inspect, attend training sessions, and seminars to stay informed about the Company's medical business operations as provided by the government. This enables the Company to comply with announcements, rules, regulations, and relevant laws accurately and to meet the established standards. Furthermore, it emphasizes that responsible personnel must ensure that the Company obtains and maintains the licenses required for its business operations. They must also ensure that there are no grounds to revoke these licenses. The management team will adhere to various regulatory requirements, including newly issued regulations, to effectively plan the Company's business operations and adapt to any necessary changes promptly. This approach enables uninterrupted business operations.
This could lead to patient criticism on social media, complaints to relevant agencies, and potential legal action. Therefore, the Group is at risk of being sued due to patient dissatisfaction with the treatment outcomes or potential implications related to the medical care provided by the physicians and specialists within the Company. The Group and/or the physicians may be required to compensate the claimant, which can impact the future performance and reputation of the Group.
The Group has consistently developed the quality of its services, prioritizing safety. This includes selecting experienced and skilled physicians and personnel, establishing policies and procedures for treatment, assessing the patient's mental condition, and obtaining clear and explicit consent through documents such as consent letters that specify the relevant laws or regulations. Additionally, the Group regularly assesses the quality of service, particularly in medical treatment and patient satisfaction when customers receive services and treatment from the Group. These measures allow the Group to continuously monitor operational efficiency and the quality of service delivery. The established procedures also indirectly aim to prevent potential legal claims and various damages that may occur. The processes are also implemented, controlled, and monitored within a consistent framework, process, and policy across all service branches. This is to maintain the Group’s uniform service quality standards. It involves regular training for personnel based on their roles and responsibilities to enhance their skills and expertise in their work. Furthermore, the Group has established a risk management working group to comply with sound corporate governance principles. Their role is to identify, assess, and monitor risks, as well as manage them effectively, to minimize potential risks systematically and efficiently. In 2025, the Group had no lawsuits claiming damages resulting for medical treatment services that had any significant impact on the Group.
The Group may face future challenges due to a shortage of these personnel.
Historically, the Group did not experience any shortage of personnel. The average employee turnover rate in the Group was 0.67% in 2025. Acknowledging the significance of medical personnel, the Group has implemented a talent management policy. This includes the following incentives. 1) The Group recruits personnel with knowledge, skills, experience, and values that align with the Group's organizational culture, both through its own recruitment channels and in collaboration with external agencies. 2) The Group establishes compensation, welfare, and benefits that are commensurate with the individual's experience, knowledge, and abilities, and can be compared to those offered by other companies. 3) The Group prioritizes personnel development and provides career pathways that support employees in all positions. It encourages further studies relevant to their roles and responsibilities and ensures regular participation in training programs and site visits organized by both internal and external entities, including educational and research institutions, both domestically and internationally. Moreover, Group personnel may also serve as consultants or trainers, sharing their knowledge with individuals both domestically and internationally. 4) The Company evaluates its employees and makes necessary adjustments to ensure that compensation, welfare, and performance benefits are commensurate with employees' abilities and job positions. This approach aims to motivate employees and encourage their personal development. 5) The Group regularly reviews its manpower plan to ensure a continuous supply of knowledgeable, skilled, and experienced personnel who are ready to fulfil their roles effectively. It also establishes a succession plan for key positions, considering performance and potential, particularly in leadership, and alignment with corporate values.
The rapid advancement of medical technology may impact the Company's financial position, operating results, and business prospects, as well as customer satisfaction and future customer demands.
The Company's executives and working group continuously monitor news and advancements in medical technology related to assisted reproductive technology. They also assess the necessity and suitability of adopting new, efficient technologies that adhere to international standards, ensure high security, and have the potential for economic benefits. The Company encourages relevant personnel to regularly participate in academic conferences and seminars organized by government agencies or trusted medical institutions. Additionally, it establishes action plans for senior executives to present new innovations to the Board of Directors and medical experts, including scientists. This demonstrates the Company's excellent potential in adapting to changes in technology, treatment methods, and medical instruments, and equipment. By continuously selecting and importing new technologies, the Company has achieved a high success rate in treatments and consistently improved its performance. These innovative technologies have gained significant popularity in infertility treatment centers throughout Thailand. The Group is committed to preserving this capability to ensure continuous operations and development consistent with its strategic and business objectives.
The Company may face the risk of lease agreement non-renewal or an increase in rental and service rates. These risks may impact the Company's operational continuity.
Throughout the Company's past operations since its establishment, the owners of the rental spaces have never terminated the Company's lease agreements. Moreover, the Company has the ability to renew the lease agreements at any time. Under the majority of the lease agreements, the Company may negotiate lease renewals upon expiration. The leases include clearly defined rental rate adjustment terms. The Company continues to foster and maintain positive relationships with all lessors by consistently making timely rental payments and faithfully adhering to the terms of the leases.
- The loss of key executives may result in delays in management, policy formulation, or strategic decision-making, and may affect the continuity of the Company’s operations. - In the absence of suitably qualified successors with sufficient understanding of the business, the execution of strategies or business plans may not achieve the intended objectives. - Unexpected changes in key executives may also adversely affect the confidence of shareholders, investors, employees, and other stakeholders in the Company’s stability and strategic direction
The Group acknowledges the potential risks and has implemented an adequate internal control system. It has also established guidelines for risk reduction in accordance with the criteria specified in the Capital Market Supervisory Board's notification. The Company has a well-defined organizational structure that specifies the scope of authority, responsibilities, and approval authority for each position and department. It also has a system in place to carefully select personnel with relevant experience and suitability for their respective positions. The Group has also implemented a succession plan to effectively manage personnel, ensuring a suitable decentralization of power and mitigating the risks. Furthermore, the Group benefits from a management team comprising predominantly long-term employees who have been working with the Group for an average of over 10 years, including physicians and key medical personnel. This tenure ensures that they possess extensive experience, knowledge, and a deep understanding of the infertility service business.
Shareholder Risk
- The Company’s decision-making may be primarily influenced by major shareholders. As a result, certain decisions may not equally reflect the interests of all shareholders and may not align with the long-term interests of the Company or its shareholders as a whole. - Minority shareholders may be unable to consolidate sufficient voting power to effectively monitor or counterbalance proposals made by major shareholders. - In the absence of appropriate checks and balances, this may adversely affect transparency, investor confidence, and the overall attractiveness of the Company as an investment.
The Company acknowledges these risks and has included in its Board of Directors three independent directors who serve as members of the Audit Committee. Their role is to audit and balance the operations of the Board of Directors and the Company's executives. All members of the Audit Committee are highly qualified and widely recognized in society. The management structure has clearly and transparently defined the scope of authority, responsibilities, and duties of various committees. Additionally, comprehensive measures have been established, and the Board of Directors recognizes the importance of complying with policies related to the principles of good corporate governance. The Company will strictly comply with the principles of good corporate governance. Furthermore, the Company has established clear boundaries of authority and an approval authority table for each level of transactions within appropriate scopes or monetary limits, including those involving major shareholders, individuals with controlling powers, and potential conflicts of interest.
Unlock full benchmarking
Claim this company to see every KPI your sector qualifies for, from 70+ across the market, benchmarked against sector peers.

